Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. more
Time Frame | ERAS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.43% | -2.06% | -0.55% |
1-Month Return | -8.79% | -1.92% | 2.72% |
3-Month Return | -13.84% | -10.4% | 7.66% |
6-Month Return | 22.06% | -4.6% | 10.15% |
1-Year Return | 35.33% | 4.06% | 27.53% |
3-Year Return | -81.93% | 1.94% | 32.31% |
5-Year Return | -85.71% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 310.00K | 540.00K | 829.00K | 2.64M | 3.73M | [{"date":"2019-12-31","value":8.31,"profit":true},{"date":"2020-12-31","value":14.47,"profit":true},{"date":"2021-12-31","value":22.21,"profit":true},{"date":"2022-12-31","value":70.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (310.00K) | (540.00K) | (829.00K) | (2.64M) | (3.73M) | [{"date":"2019-12-31","value":-31000000,"profit":false},{"date":"2020-12-31","value":-54000000,"profit":false},{"date":"2021-12-31","value":-82900000,"profit":false},{"date":"2022-12-31","value":-264100000,"profit":false},{"date":"2023-12-31","value":-373200000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 13.29M | 37.51M | 96.54M | 145.45M | 141.53M | [{"date":"2019-12-31","value":9.14,"profit":true},{"date":"2020-12-31","value":25.79,"profit":true},{"date":"2021-12-31","value":66.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.3,"profit":true}] |
Operating Income | (13.29M) | 34.24M | (124.88M) | (247.45M) | (141.53M) | [{"date":"2019-12-31","value":-38.83,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-364.75,"profit":false},{"date":"2022-12-31","value":-722.73,"profit":false},{"date":"2023-12-31","value":-413.36,"profit":false}] |
Total Non-Operating Income/Expense | 2.56M | 7.93M | 2.31M | 9.55M | 31.84M | [{"date":"2019-12-31","value":8.03,"profit":true},{"date":"2020-12-31","value":24.9,"profit":true},{"date":"2021-12-31","value":7.25,"profit":true},{"date":"2022-12-31","value":29.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (12.04M) | (101.66M) | (122.76M) | (242.81M) | (125.04M) | [{"date":"2019-12-31","value":-1204000000,"profit":false},{"date":"2020-12-31","value":-10166000000,"profit":false},{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-12504200000,"profit":false}] |
Income Taxes | (1.30M) | 71.41M | 27.33M | (4.64M) | - | [{"date":"2019-12-31","value":-1.82,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":38.27,"profit":true},{"date":"2022-12-31","value":-6.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (10.74M) | (173.07M) | (150.09M) | (238.16M) | - | [{"date":"2019-12-31","value":-1073700000,"profit":false},{"date":"2020-12-31","value":-17306900000,"profit":false},{"date":"2021-12-31","value":-15009000000,"profit":false},{"date":"2022-12-31","value":-23816000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (12.04M) | (101.66M) | (122.76M) | (242.81M) | (230.59M) | [{"date":"2019-12-31","value":-1204000000,"profit":false},{"date":"2020-12-31","value":-10166000000,"profit":false},{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-23059100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.74M) | (173.07M) | (150.09M) | (238.16M) | (125.04M) | [{"date":"2019-12-31","value":-1073700000,"profit":false},{"date":"2020-12-31","value":-17306900000,"profit":false},{"date":"2021-12-31","value":-15009000000,"profit":false},{"date":"2022-12-31","value":-23816000000,"profit":false},{"date":"2023-12-31","value":-12504200000,"profit":false}] |
EPS (Diluted) | (0.96) | (0.68) | (2.67) | (1.96) | (0.83) | [{"date":"2019-12-31","value":-95.55,"profit":false},{"date":"2020-12-31","value":-67.52,"profit":false},{"date":"2021-12-31","value":-266.5,"profit":false},{"date":"2022-12-31","value":-196,"profit":false},{"date":"2023-12-31","value":-83,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ERAS | |
---|---|
Cash Ratio | 10.62 |
Current Ratio | 11.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ERAS | |
---|---|
ROA (LTM) | -19.14% |
ROE (LTM) | -38.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ERAS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ERAS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.65 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Erasca Inc (ERAS) share price today is $2.49
Yes, Indians can buy shares of Erasca Inc (ERAS) on Vested. To buy Erasca Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ERAS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Erasca Inc (ERAS) via the Vested app. You can start investing in Erasca Inc (ERAS) with a minimum investment of $1.
You can invest in shares of Erasca Inc (ERAS) via Vested in three simple steps:
The 52-week high price of Erasca Inc (ERAS) is $3.45. The 52-week low price of Erasca Inc (ERAS) is $1.64.
The price-to-earnings (P/E) ratio of Erasca Inc (ERAS) is
The price-to-book (P/B) ratio of Erasca Inc (ERAS) is 1.65
The dividend yield of Erasca Inc (ERAS) is 0.00%
The market capitalization of Erasca Inc (ERAS) is $740.74M
The stock symbol (or ticker) of Erasca Inc is ERAS